{"id":742173,"date":"2012-11-01T18:00:00","date_gmt":"2012-11-01T18:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/"},"modified":"2023-03-22T00:04:21","modified_gmt":"2023-03-22T04:04:21","slug":"merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/","title":{"rendered":"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx"},"content":{"rendered":"<p>\n      Merck, known as MSD outside the United States and Canada, today<br \/>\n      confirmed terms of an agreement with plaintiffs to resolve <i>Plubell v.<br \/>\n      Merck<\/i>, an economic class action lawsuit pending in Missouri state<br \/>\n      court. The class consists of Missouri consumers who purchased Vioxx, but<br \/>\n      do not claim any physical injury, and who seek to recover damages under<br \/>\n      the Missouri Merchandising Practices Act.\n    <\/p>\n<p>\n      Under the agreement, Merck will pay to resolve all validated claims<br \/>\n      submitted by class members, approved attorneys&#8217; fees and expenses, and<br \/>\n      settlement notice costs and administrative expenses. The company<br \/>\n      recorded a charge for this settlement in the third quarter of 2012. The<br \/>\n      agreement is subject to court approval and certain conditions related to<br \/>\n      participation.\n    <\/p>\n<p>\n      &#8220;This agreement is in the best interest of the company and its<br \/>\n      shareholders. It reduces the uncertainty of litigation and ongoing<br \/>\n      defense costs, and helps us to remain focused on bringing forward<br \/>\n      innovative products and services for our customers,&#8221; said Bruce N.<br \/>\n      Kuhlik, executive vice president and general counsel of Merck.\n    <\/p>\n<p>\n      Judge Marco Roldan is presiding over the case. Merck is represented by<br \/>\n      John Beisner of Skadden, Arps, Slate Meagher &#038; Flom LLP and Doug Marvin<br \/>\n      of Williams &#038; Connolly LLP.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50463568&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=88f7db579b4db6c1f9b511ef09c91fa8\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50463568&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=091857d010bb40946bbfcfa794798e5f\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20121101006896r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ron Rogers, 908-391-4302<br \/>or<br \/>Investor:<br \/>Carol        Ferguson, 908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, known as MSD outside the United States and Canada, today confirmed terms of an agreement with plaintiffs to resolve Plubell v. Merck , an economic class action lawsuit pending in Missouri state court. The class consists of Missouri consumers who purchased Vioxx, but do not claim any physical injury, and who seek to recover damages under the Missouri Merchandising Practices Act. Under the agreement, Merck will pay to resolve all validated claims submitted by class members, approved attorneys&#8217; fees and expenses, and settlement notice costs and administrative expenses. The company recorded a charge for this settlement in the third quarter of 2012. The agreement is subject to court approval and certain conditions related to participation. &#8220;This agreement is in the best interest of the company and its shareholders. It reduces the uncertainty of litigation and ongoing defense costs, and helps us to remain focused on bringing forward innovative products and services for our<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742173","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck, known as MSD outside the United States and Canada, today confirmed terms of an agreement with plaintiffs to resolve Plubell v. Merck , an economic class action lawsuit pending in Missouri state court. The class consists of Missouri consumers who purchased Vioxx, but do not claim any physical injury, and who seek to recover damages under the Missouri Merchandising Practices Act. Under the agreement, Merck will pay to resolve all validated claims submitted by class members, approved attorneys&#039; fees and expenses, and settlement notice costs and administrative expenses. The company recorded a charge for this settlement in the third quarter of 2012. The agreement is subject to court approval and certain conditions related to participation. &quot;This agreement is in the best interest of the company and its shareholders. It reduces the uncertainty of litigation and ongoing defense costs, and helps us to remain focused on bringing forward innovative products and services for our\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/\",\"name\":\"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2012-11-01T18:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/","og_locale":"en_US","og_type":"article","og_title":"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx - Merck.com","og_description":"Merck, known as MSD outside the United States and Canada, today confirmed terms of an agreement with plaintiffs to resolve Plubell v. Merck , an economic class action lawsuit pending in Missouri state court. The class consists of Missouri consumers who purchased Vioxx, but do not claim any physical injury, and who seek to recover damages under the Missouri Merchandising Practices Act. Under the agreement, Merck will pay to resolve all validated claims submitted by class members, approved attorneys' fees and expenses, and settlement notice costs and administrative expenses. The company recorded a charge for this settlement in the third quarter of 2012. The agreement is subject to court approval and certain conditions related to participation. \"This agreement is in the best interest of the company and its shareholders. It reduces the uncertainty of litigation and ongoing defense costs, and helps us to remain focused on bringing forward innovative products and services for our","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:21+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/","name":"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx","datePublished":"2012-11-01T18:00:00+00:00","dateModified":"2023-03-22T04:04:21+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121101006896r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-missouri-consumer-class-action-lawsuit-related-to-vioxx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"1498b4c8-32c9-4e1f-a2f7-91b10fb351ba","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742173\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742173"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}